FBIO News and Press, Fortress Biotech Inc. From 11/20/23

Fortress Biotech, Inc. (NASDAQ: FBIO) is one of today's top gainers. The company's shares have moved -3.93% on the day to $1.71. Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products,...

2023-11-20 10:17:26 ET Whether you’re looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week with Thursday’s Thanksgivin...

2023-11-20 10:00:12 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Fortress Biote...

2023-11-17 13:32:10 ET Ever wonder what signals to look for in the stock market today? Let’s talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch. Why Insider Buying Matters in Penny S...

2023-11-17 12:41:25 ET Gainers: Altamira Therapeutics Ltd ( CYTO ) +255% . Safe and Green Development Corp ( SGD ) +89% . Fortress Biotech ( FBIO ) +50% . Mural Oncology Plc ( MURA ) +40% . Syntec Optics Holdings ( OPTX ) +35% . ...

2023-11-17 08:36:02 ET Safe and Green Development  ( SGD ) +165% . Mural Oncology  ( MURA ) +62% . La Rosa Holdings ( LRHC ) +12% to Launch its First Office Location in Houston, Texas Gap ( GPS ) +19% Q3 earnings call release Synte...

2023-11-14 16:31:20 ET More on Fortress Biotech Fortress Biotech announces pricing of $10M public offering Fortress Biotech announces launch of proposed public offering Seeking Alpha’s Quant Rating on Fortress Biotech Historical earnings data for Fortr...

Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net revenue of $17.4 million in the second quarter of 2023 Fortress is advancing several late-stage clinical assets with three potential NDA and BLA submissions to FD...

WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and...

MIAMI, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product c...